Cargando…

Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma

BACKGROUND: Lung large-cell neuroendocrine carcinoma (L-LCNEC) is a rare and highly aggressive neuroendocrine tumor. There is currently no standard therapeutic regimen, and systemic chemotherapy results in poor prognosis. Due to the rarity of L-LCNEC, the efficacy and safety of immune checkpoint inh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Zheng, Wei, Jingwen, Xu, Manyi, Song, Zhengbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482626/ https://www.ncbi.nlm.nih.gov/pubmed/37691658 http://dx.doi.org/10.21037/jtd-23-348

Ejemplares similares

Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma
por: Wei, Jingwen, et al.
Publicado: (2023)

Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer
por: Xu, Manyi, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study
por: Xiang, Jing, et al.
Publicado: (2023)

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status
por: Chauhan, Aman, et al.
Publicado: (2018)

Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study
por: Gu, Xiaodong, et al.
Publicado: (2022)

Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis
por: Meng, Lingbin, et al.
Publicado: (2023)

Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations
por: Hao, Yue, et al.
Publicado: (2023)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
por: Si, Jinfei, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
por: Gubbi, Sriram, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
por: Gu, Xiaodong, et al.
Publicado: (2023)

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
por: Lee, Jiyun, et al.
Publicado: (2020)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
por: Bongiovanni, Alberto, et al.
Publicado: (2021)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
por: Wang, Victoria E., et al.
Publicado: (2017)

Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System
por: Xing, Jiazhang, et al.
Publicado: (2020)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis
por: Jácome, Alexandre A., et al.
Publicado: (2021)

Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy
por: Nishimura, Tadashi, et al.
Publicado: (2022)

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis
por: Peng, Min, et al.
Publicado: (2018)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
por: van Akkooi, Alexander C. J., et al.
Publicado: (2022)

A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world
por: Shi, Yue, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer
por: Chikaishi, Yasuhiro, et al.
Publicado: (2021)

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
por: Gu, Yi-Min, et al.
Publicado: (2021)

Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma
por: Hao, Yue, et al.
Publicado: (2022)

Efficacy of Immune Checkpoint Inhibitors against Advanced or Metastatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
por: Park, Eun-Joo, et al.
Publicado: (2022)

The efficacy and safety of anlotinib treatment for advanced lung cancer
por: Shao, Lan, et al.
Publicado: (2019)

Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population
por: Yu, Xiaoyuan, et al.
Publicado: (2022)

Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis
por: Cai, Zijing, et al.
Publicado: (2022)

What is the role of checkpoint inhibitors in neuroendocrine neoplasms?
por: Al-Toubah, Taymeyah, et al.
Publicado: (2020)

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
por: Tang, Hui, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis
por: Feng, Yu, et al.
Publicado: (2023)

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma
por: Li, Jinpeng, et al.
Publicado: (2023)

Effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients
por: Zhou, Huan, et al.
Publicado: (2023)

Effects of intrapericardial administration after catheter drainage on malignant pericardial effusion in non‐small cell lung cancer: A real‐world study
por: Wei, Jingwen, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis
por: Xian, Feng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_abnlolom18pbgec3h3t91o6qie